David Baxter PhD
Late Founder
Treating anxiety during pregnancy: Just how safe are SSRIs?
by Deborah B. Raphael, Jessica Ross, Louann Brizendine, MD
Psychiatry Online, Vol. 7, No. 2 / February 2008
Staggering SSRI and benzodiazepine use during the first and third trimesters may help reduce potential risks to the fetus.
To help you and your patients weigh the risks and benefits of perinatal treatments for anxiety disorders, this article briefly summarizes the evidence on:
Nearly one-third of women experience an anxiety disorder during their lives, with peak onset during childbearing years.1 Compared with research on perinatal depression, far fewer studies have examined anxiety disorders? onset, presentation, prevalence, and treatment.
The literature includes no studies of the course of preexisting GAD or posttraumatic stress disorder (PTSD) and no evidence that symptoms of preexisting obsessive-compulsive disorder (OCD) change during pregnancy. Some studies of panic disorder show symptoms improving during pregnancy, whereas others do not (Table 1).
One small study done in late pregnancy found a significant association between the prevalence of an anxiety disorder, maternal primiparity, and comorbid medical conditions. Thus, a woman in her first pregnancy may be at increased risk to develop an anxiety disorder if she has a comorbid medical condition. As in the case of Ms. K, however, continuation of preexisting anxiety appears more likely than onset of a new anxiety disorder during pregnancy.
Fetal risks from maternal anxiety
Fetal risk from severe maternal anxiety is not zero. Offspring born to high-anxiety mothers exhibit neurobehavioral differences compared with offspring of calmer mothers. Changes in high-anxiety mothers? offspring include:
Exposure to maternal high anxiety has been associated with mental developmental delays in infants and increased risk for behavioral and emotional problems in young children. Anxiety may not directly cause intrauterine growth retardation and preterm delivery, but it is significantly associated with prenatal tobacco, alcohol, and narcotics use?which predicts these and other negative neonatal outcomes.
Anxiety during pregnancy is a risk factor for postnatal depressive symptoms, independent of depressed mood and family or marital stressors during pregnancy. Mothers with postpartum depression appear less able to respond sensitively and competently to their newborns, and these infants may be at increased risk of behavioral, emotional, and cognitive problems.
Ideally you?ll begin treating anxiety disorders in women of childbearing age with preconception psychoeducation. Explaining the risks of medications if she were to become pregnant and asking about the contraception she is using are de rigueur. Psychotherapy is low risk to the fetus and is considered first choice for treating mild to moderate anxiety in women of childbearing age who plan to become pregnant (Box).
Psychotherapy alone is inadequate, however, for the many patients?such as Ms. K?who present already pregnant with a history of moderate to severe anxiety. Adjunctive psychotropic therapy?along with various nonmedication therapies?is warranted for patients whose social or occupational functioning would be substantially impaired by suboptimal control of anxiety during pregnancy.
Because Ms. K wishes to continue taking paroxetine and clonazepam, what can you tell her about the risks and benefits of SSRIs and benzodiazepines during pregnancy?
SSRIs in pregnancy
Teratogenicity. Compared with benzodiazepines, SSRIs have been considered agents of choice for use during pregnancy because of a lower risk of teratogenic effects. Paroxetine (Paxil), however, appears to pose a greater risk for teratogenicity than other SSRIs.
An increased risk for fetal ventricular and/or atrial septal defects has been associated with first-trimester exposure to paroxetine, but no other SSRI. First trimester exposure to paroxetine at doses averaging 25 mg/d has been associated with statistically significant risks of major congenital anomalies (2-fold increase) and major cardiac anomalies (3-fold increase), although other studies have failed to reproduce this finding. A meta-analysis of 7 studies by Bar-Oz et al found an association between first-trimester paroxetine exposure and a significant increase in risk for cardiac malformations (odds ratio [OR] 1.72; 95% CI,1.22-2.42).
The overall rate of fetal malformations from SSRIs appears to be low, although most studies have examined only fluoxetine or paroxetine. Some studies have reported various malformations with fluoxetine or sertraline, but others have not. In Finland, a population-based study found no increase in rate of major congenital malformations in offspring of 1,782 women who filled prescriptions for SSRIs during pregnancy, compared with the general population rate of 1% to 3%.
Neurobehavioral effects. SSRI exposure during fetal life has shown no long-term neurobehavioral effects. A blinded prospective study by Nulman et al22 found no differences in global IQ scores, language development, or behavioral development among children age ≤5 who were exposed in utero to fluoxetine (n=40) or a tricyclic antidepressant (n=46), compared with unexposed children of nondepressed mothers (n=36). Similarly, using reports from teachers and clinical measures of internalizing behaviors, Misri et al found no increase in depression, anxiety, or withdrawal in 4-year-olds with prenatal exposure to SSRIs (n=22), compared with nonexposed children (n=14).
Pulmonary hypertension. SSRI exposure in later pregnancy may increase the rate of persistent pulmonary hypertension of the newborn (PPHN), which occurs in 1 to 2 infants per 1,000 live births. PPHN showed a statistically significant association with late prenatal SSRI exposure (OR 6.1) in a study that controlled for maternal smoking, body mass index, and diabetes. PPHN occurred in approximately 1% of infants exposed to SSRIs in late pregnancy. PPHN rates were not affected by maternal depression/anxiety, non-SSRI antidepressant exposure throughout pregnancy, or SSRI exposure during early pregnancy only.
Toxicity and withdrawal syndromes. Infants of women who continue to take SSRIs just before delivery can develop toxicity or withdrawal syndromes. Occurrence of either syndrome depends on SSRI half-life, serum concentration, and the pharmacodynamics of other medications given during pregnancy and labor.
Discontinuation syndromes can occur in SSRI-exposed neonates within a few hours or days after birth and last up to 1 month after delivery, depending on the infant?s susceptibility. Nearly two-thirds of suspected SSRI-induced neonatal withdrawal syndromes have been associated with paroxetine, although all SSRIs appear be associated with some risk. Several trials, including a recent prospective study, found prenatal antidepressant use associated with lower gestational age at birth and increased risk of preterm birth.
A prospective study compared the effects of maternal SSRI use on behavioral state, sleep, motor activity, and heart rate variability in 17 exposed vs 17 nonexposed matched neonates. In the first 1 to 2 weeks of life, SSRI-exposed neonates showed:
Recommendations. The perception that SSRIs have low fetal toxicity has guided prescribing practices in recent years. Newer evidence shows, however, that fetal exposure to SSRIs may have some adverse effects, including lower birth weight and early delivery. First-trimester paroxetine use has been associated with increased risk for fetal ventricular and/or atrial septal defects.
Discuss these risks with the patient when you consider starting or continuing SSRI use during pregnancy. If you prescribe an SSRI, use the minimum effective dosage and avoid paroxetine during pregnancy.
To reduce the risk for PPHN, early delivery, and neonatal withdrawal syndromes, taper and discontinue the SSRI during the third trimester. Restarting the SSRI soon after delivery is the most effective way to prevent recurrence of anxiety symptoms or postpartum depression.
Benzodiazepines
Teratogenicity. Like SSRIs, benzodiazepines cross the placenta to the fetus. Benzodiazepine teratogenicity remains controversial. Some?but not all?data show a small but significant increased risk for major malformations/oral cleft malformations with first-trimester benzodiazepine exposure.
A Medline literature search from 1966 to 2000 found not enough information to determine whether potential benefits of benzodiazepines to the mother outweigh risks to the fetus. An ambitious meta-analysis of >1,400 studies by Dolovich et al30 found a small association between fetal exposure to benzodiazepines and major malformations/cleft palate, but only in pooled data from case-controlled studies. No association was found between fetal exposure to benzodiazepines and malformations/cleft palate in pooled data from cohort studies.
A 32-month, hospital-based surveillance program of 28,565 births found no increase in the rate of major malformations in 43 infants exposed to clonazepam monotherapy?33 (77%) in the first trimester. Thus, the risk of major malformations/cleft palate with the use of benzodiazepines in the first trimester appears to be low.
Toxicity and withdrawal syndromes. Neonatal benzodiazepine toxicity and withdrawal syndromes have been reported in studies and case reports. Although these syndromes occur, they do not affect all infants with late third-trimester benzodiazepine exposure. Prevalence rates have not been calculated.
Neonatal toxicity (?floppy infant syndrome?)?characterized by hypothermia, lethargy, poor respiratory effort, and feeding difficulties?occurs after maternal benzodiazepine use just before delivery.
Neonatal withdrawal may be caused by very late, third trimester exposure to benzodiazepines. Symptoms?which can persist ≤3 months after delivery?include restlessness, irritability, abnormal sleep patterns, suckling difficulties, growth retardation, hypertonia, hyperreflexia, tremulousness, apnea, diarrhea, and vomiting.
Recommendations. When possible, avoid benzodiazepines in the first trimester because of possible teratogenicity and then again late in the third trimester before delivery because of neonatal withdrawal syndromes. To reduce as much as possible the small risk of a benzodiazepine-related fetal malformation/cleft palate, wean the mother from benzodiazepines before conception. After the first trimester, the benzodiazepine can be restarted if necessary.
To minimize neonatal withdrawal, gradually taper the mother?s benzodiazepine before delivery. Because the baby?s due date is calculated to be ?2 weeks before delivery, begin this taper 3 to 4 weeks before the due date and discontinue at least 1 week before delivery. Breastfeeding while taking benzodiazepines is not recommended because of the risk of over-sedating the infant.
A rational approach
Both benzodiazepines and SSRIs are associated with low but demonstrated risks to the fetus when used during pregnancy (Table 2). Use these medications to manage a patient?s anxiety only if the clinical benefit to the mother justifies the potential risks to the fetus.
A staggered combination of SSRIs during the first 2 trimesters and benzodiazepines during the last 2 trimesters can help balance the risks and benefits of pharmacotherapy of anxiety disorders during pregnancy (Table 3).
Frankly discuss with your patient the risks and benefits in the context of her perceived need for symptom control to sustain her level of functioning. You could document this discussion in the progress note as ?R, B, A, and pt C,? signifying that risks, benefits, and alternatives were discussed, and the patient consented. If possible, include the patient?s husband, partner, or parent in this discussion.
Clonazepam ? Klonopin
Paroxetine ? Paxil
Fluoxetine ? Prozac
Sertraline ? Zoloft
1 For references, tables, and boxes, see full report in attached Adobe Acrobat format.
by Deborah B. Raphael, Jessica Ross, Louann Brizendine, MD
Psychiatry Online, Vol. 7, No. 2 / February 2008
Staggering SSRI and benzodiazepine use during the first and third trimesters may help reduce potential risks to the fetus.
Ms. K, age 25, is 6 weeks pregnant and is taking medications for generalized anxiety disorder (GAD). When she was diagnosed with GAD at age 19, her symptoms included 6 months of excessive anxiety?insomnia, fatigue, difficulty with concentration, and psychomotor agitation?without mood symptoms. These symptoms interfered greatly with her schoolwork and other daily activities.
For 6 years Ms. K has been taking the selective serotonin reuptake inhibitor (SSRI) paroxetine, 15 mg/d, and the benzodiazepine clonazepam, 0.5 mg as needed, with good symptom control. Now that she is pregnant and her primary care doctor has refused to continue these medications, she is seeking treatment and advice.
Not enough is known about how to safely treat anxiety disorders during pregnancy, and physicians are not sure what to do with patients such as Ms. K. Without evidence-based guidelines, we feel anxious about potential risks to mother and fetus as we try to provide appropriate drug therapy.For 6 years Ms. K has been taking the selective serotonin reuptake inhibitor (SSRI) paroxetine, 15 mg/d, and the benzodiazepine clonazepam, 0.5 mg as needed, with good symptom control. Now that she is pregnant and her primary care doctor has refused to continue these medications, she is seeking treatment and advice.
To help you and your patients weigh the risks and benefits of perinatal treatments for anxiety disorders, this article briefly summarizes the evidence on:
- anxiety disorders? natural history during pregnancy
- how untreated maternal anxiety affects the fetus
- nonpharmacologic therapies for anxiety disorders
- a plan to manage fetal risks by staggering SSRI and benzodiazepine use during the first and third trimesters.
Nearly one-third of women experience an anxiety disorder during their lives, with peak onset during childbearing years.1 Compared with research on perinatal depression, far fewer studies have examined anxiety disorders? onset, presentation, prevalence, and treatment.
The literature includes no studies of the course of preexisting GAD or posttraumatic stress disorder (PTSD) and no evidence that symptoms of preexisting obsessive-compulsive disorder (OCD) change during pregnancy. Some studies of panic disorder show symptoms improving during pregnancy, whereas others do not (Table 1).
One small study done in late pregnancy found a significant association between the prevalence of an anxiety disorder, maternal primiparity, and comorbid medical conditions. Thus, a woman in her first pregnancy may be at increased risk to develop an anxiety disorder if she has a comorbid medical condition. As in the case of Ms. K, however, continuation of preexisting anxiety appears more likely than onset of a new anxiety disorder during pregnancy.
Fetal risks from maternal anxiety
Fetal risk from severe maternal anxiety is not zero. Offspring born to high-anxiety mothers exhibit neurobehavioral differences compared with offspring of calmer mothers. Changes in high-anxiety mothers? offspring include:
- altered EEG activation and vagal tone
- increased time in deep sleep and less time in active alert states
- lower performance on the Brazelton Neonatal Behavior Assessment Scale.
Exposure to maternal high anxiety has been associated with mental developmental delays in infants and increased risk for behavioral and emotional problems in young children. Anxiety may not directly cause intrauterine growth retardation and preterm delivery, but it is significantly associated with prenatal tobacco, alcohol, and narcotics use?which predicts these and other negative neonatal outcomes.
Anxiety during pregnancy is a risk factor for postnatal depressive symptoms, independent of depressed mood and family or marital stressors during pregnancy. Mothers with postpartum depression appear less able to respond sensitively and competently to their newborns, and these infants may be at increased risk of behavioral, emotional, and cognitive problems.
CASE CONTINUED: ?Stay the course?
Ms. K worries that she could not tolerate recurrence of her anxiety symptoms and wishes to continue both medications. Her husband concurs, but they want to minimize potential risks to their baby. You discuss the options for treating anxiety symptoms during pregnancy, including medications, psychotherapy, and behavioral treatments.
Treatment decisionsMs. K worries that she could not tolerate recurrence of her anxiety symptoms and wishes to continue both medications. Her husband concurs, but they want to minimize potential risks to their baby. You discuss the options for treating anxiety symptoms during pregnancy, including medications, psychotherapy, and behavioral treatments.
Ideally you?ll begin treating anxiety disorders in women of childbearing age with preconception psychoeducation. Explaining the risks of medications if she were to become pregnant and asking about the contraception she is using are de rigueur. Psychotherapy is low risk to the fetus and is considered first choice for treating mild to moderate anxiety in women of childbearing age who plan to become pregnant (Box).
Psychotherapy alone is inadequate, however, for the many patients?such as Ms. K?who present already pregnant with a history of moderate to severe anxiety. Adjunctive psychotropic therapy?along with various nonmedication therapies?is warranted for patients whose social or occupational functioning would be substantially impaired by suboptimal control of anxiety during pregnancy.
Because Ms. K wishes to continue taking paroxetine and clonazepam, what can you tell her about the risks and benefits of SSRIs and benzodiazepines during pregnancy?
SSRIs in pregnancy
Teratogenicity. Compared with benzodiazepines, SSRIs have been considered agents of choice for use during pregnancy because of a lower risk of teratogenic effects. Paroxetine (Paxil), however, appears to pose a greater risk for teratogenicity than other SSRIs.
An increased risk for fetal ventricular and/or atrial septal defects has been associated with first-trimester exposure to paroxetine, but no other SSRI. First trimester exposure to paroxetine at doses averaging 25 mg/d has been associated with statistically significant risks of major congenital anomalies (2-fold increase) and major cardiac anomalies (3-fold increase), although other studies have failed to reproduce this finding. A meta-analysis of 7 studies by Bar-Oz et al found an association between first-trimester paroxetine exposure and a significant increase in risk for cardiac malformations (odds ratio [OR] 1.72; 95% CI,1.22-2.42).
The overall rate of fetal malformations from SSRIs appears to be low, although most studies have examined only fluoxetine or paroxetine. Some studies have reported various malformations with fluoxetine or sertraline, but others have not. In Finland, a population-based study found no increase in rate of major congenital malformations in offspring of 1,782 women who filled prescriptions for SSRIs during pregnancy, compared with the general population rate of 1% to 3%.
Neurobehavioral effects. SSRI exposure during fetal life has shown no long-term neurobehavioral effects. A blinded prospective study by Nulman et al22 found no differences in global IQ scores, language development, or behavioral development among children age ≤5 who were exposed in utero to fluoxetine (n=40) or a tricyclic antidepressant (n=46), compared with unexposed children of nondepressed mothers (n=36). Similarly, using reports from teachers and clinical measures of internalizing behaviors, Misri et al found no increase in depression, anxiety, or withdrawal in 4-year-olds with prenatal exposure to SSRIs (n=22), compared with nonexposed children (n=14).
Pulmonary hypertension. SSRI exposure in later pregnancy may increase the rate of persistent pulmonary hypertension of the newborn (PPHN), which occurs in 1 to 2 infants per 1,000 live births. PPHN showed a statistically significant association with late prenatal SSRI exposure (OR 6.1) in a study that controlled for maternal smoking, body mass index, and diabetes. PPHN occurred in approximately 1% of infants exposed to SSRIs in late pregnancy. PPHN rates were not affected by maternal depression/anxiety, non-SSRI antidepressant exposure throughout pregnancy, or SSRI exposure during early pregnancy only.
Toxicity and withdrawal syndromes. Infants of women who continue to take SSRIs just before delivery can develop toxicity or withdrawal syndromes. Occurrence of either syndrome depends on SSRI half-life, serum concentration, and the pharmacodynamics of other medications given during pregnancy and labor.
Discontinuation syndromes can occur in SSRI-exposed neonates within a few hours or days after birth and last up to 1 month after delivery, depending on the infant?s susceptibility. Nearly two-thirds of suspected SSRI-induced neonatal withdrawal syndromes have been associated with paroxetine, although all SSRIs appear be associated with some risk. Several trials, including a recent prospective study, found prenatal antidepressant use associated with lower gestational age at birth and increased risk of preterm birth.
A prospective study compared the effects of maternal SSRI use on behavioral state, sleep, motor activity, and heart rate variability in 17 exposed vs 17 nonexposed matched neonates. In the first 1 to 2 weeks of life, SSRI-exposed neonates showed:
- greater tremulousness
- less flexible and dampened state regulation
- more time in uninterrupted REM sleep
- more frequent startles or sudden arousals
- greater generalized motor activity
- greater autonomic dysregulation.
- tremor (37/60)
- GI disturbances (34/60)?including exaggerated sucking, poor feeding, regurgitation, vomiting, and loose stools
- sleep disturbance (21/60).
Recommendations. The perception that SSRIs have low fetal toxicity has guided prescribing practices in recent years. Newer evidence shows, however, that fetal exposure to SSRIs may have some adverse effects, including lower birth weight and early delivery. First-trimester paroxetine use has been associated with increased risk for fetal ventricular and/or atrial septal defects.
Discuss these risks with the patient when you consider starting or continuing SSRI use during pregnancy. If you prescribe an SSRI, use the minimum effective dosage and avoid paroxetine during pregnancy.
To reduce the risk for PPHN, early delivery, and neonatal withdrawal syndromes, taper and discontinue the SSRI during the third trimester. Restarting the SSRI soon after delivery is the most effective way to prevent recurrence of anxiety symptoms or postpartum depression.
Benzodiazepines
Teratogenicity. Like SSRIs, benzodiazepines cross the placenta to the fetus. Benzodiazepine teratogenicity remains controversial. Some?but not all?data show a small but significant increased risk for major malformations/oral cleft malformations with first-trimester benzodiazepine exposure.
A Medline literature search from 1966 to 2000 found not enough information to determine whether potential benefits of benzodiazepines to the mother outweigh risks to the fetus. An ambitious meta-analysis of >1,400 studies by Dolovich et al30 found a small association between fetal exposure to benzodiazepines and major malformations/cleft palate, but only in pooled data from case-controlled studies. No association was found between fetal exposure to benzodiazepines and malformations/cleft palate in pooled data from cohort studies.
A 32-month, hospital-based surveillance program of 28,565 births found no increase in the rate of major malformations in 43 infants exposed to clonazepam monotherapy?33 (77%) in the first trimester. Thus, the risk of major malformations/cleft palate with the use of benzodiazepines in the first trimester appears to be low.
Toxicity and withdrawal syndromes. Neonatal benzodiazepine toxicity and withdrawal syndromes have been reported in studies and case reports. Although these syndromes occur, they do not affect all infants with late third-trimester benzodiazepine exposure. Prevalence rates have not been calculated.
Neonatal toxicity (?floppy infant syndrome?)?characterized by hypothermia, lethargy, poor respiratory effort, and feeding difficulties?occurs after maternal benzodiazepine use just before delivery.
Neonatal withdrawal may be caused by very late, third trimester exposure to benzodiazepines. Symptoms?which can persist ≤3 months after delivery?include restlessness, irritability, abnormal sleep patterns, suckling difficulties, growth retardation, hypertonia, hyperreflexia, tremulousness, apnea, diarrhea, and vomiting.
Recommendations. When possible, avoid benzodiazepines in the first trimester because of possible teratogenicity and then again late in the third trimester before delivery because of neonatal withdrawal syndromes. To reduce as much as possible the small risk of a benzodiazepine-related fetal malformation/cleft palate, wean the mother from benzodiazepines before conception. After the first trimester, the benzodiazepine can be restarted if necessary.
To minimize neonatal withdrawal, gradually taper the mother?s benzodiazepine before delivery. Because the baby?s due date is calculated to be ?2 weeks before delivery, begin this taper 3 to 4 weeks before the due date and discontinue at least 1 week before delivery. Breastfeeding while taking benzodiazepines is not recommended because of the risk of over-sedating the infant.
A rational approach
Both benzodiazepines and SSRIs are associated with low but demonstrated risks to the fetus when used during pregnancy (Table 2). Use these medications to manage a patient?s anxiety only if the clinical benefit to the mother justifies the potential risks to the fetus.
A staggered combination of SSRIs during the first 2 trimesters and benzodiazepines during the last 2 trimesters can help balance the risks and benefits of pharmacotherapy of anxiety disorders during pregnancy (Table 3).
Frankly discuss with your patient the risks and benefits in the context of her perceived need for symptom control to sustain her level of functioning. You could document this discussion in the progress note as ?R, B, A, and pt C,? signifying that risks, benefits, and alternatives were discussed, and the patient consented. If possible, include the patient?s husband, partner, or parent in this discussion.
CASE CONTINUED: CBT plus medication
Ms. K and her husband are open to adding weekly cognitive-behavioral therapy (CBT) for anxiety as long as she can continue her medications. You discuss the evidence regarding potential neonatal risks with paroxetine and clonazepam treatment. Because Ms. K is 6 weeks pregnant, you outline a plan for a rapid cross-taper off paroxetine and onto fluoxetine, 10 to 30 mg/d, explaining that paroxetine might pose a greater first-trimester risk of major congenital malformations and cardiac malformations. You discuss possible side effects of fluoxetine and explain a plan to taper off fluoxetine during the third trimester to reduce the risk of PPHN, early delivery, and withdrawal in the newborn.
Because Ms. K has been taking clonazepam at only 0.5 mg 1 to 2 times per week, you instruct her to stop taking the benzodiazepine for the next 6 weeks until she is through her first trimester. You also reassure her that she can use clonazepam after the first trimester, if necessary, as long as she agrees to taper off completely 1 to 2 weeks before to her due date.
You refer her to a CBT therapist and emphasize the importance of CBT, relaxation, and sleep hygiene?as well as support from her husband, family, and friends?to reduce her stress and facilitate the medication taper during her third trimester. You plan to see her monthly and co-manage her care with the CBT therapist and Ob/Gyn. You document this discussion in her medical record as evidence of informed consent.
Related resourcesMs. K and her husband are open to adding weekly cognitive-behavioral therapy (CBT) for anxiety as long as she can continue her medications. You discuss the evidence regarding potential neonatal risks with paroxetine and clonazepam treatment. Because Ms. K is 6 weeks pregnant, you outline a plan for a rapid cross-taper off paroxetine and onto fluoxetine, 10 to 30 mg/d, explaining that paroxetine might pose a greater first-trimester risk of major congenital malformations and cardiac malformations. You discuss possible side effects of fluoxetine and explain a plan to taper off fluoxetine during the third trimester to reduce the risk of PPHN, early delivery, and withdrawal in the newborn.
Because Ms. K has been taking clonazepam at only 0.5 mg 1 to 2 times per week, you instruct her to stop taking the benzodiazepine for the next 6 weeks until she is through her first trimester. You also reassure her that she can use clonazepam after the first trimester, if necessary, as long as she agrees to taper off completely 1 to 2 weeks before to her due date.
You refer her to a CBT therapist and emphasize the importance of CBT, relaxation, and sleep hygiene?as well as support from her husband, family, and friends?to reduce her stress and facilitate the medication taper during her third trimester. You plan to see her monthly and co-manage her care with the CBT therapist and Ob/Gyn. You document this discussion in her medical record as evidence of informed consent.
- Baby Center. Managing stress and anxiety during pregnancy. Patient information.
- Organization of Teratology Information Specialists (OTIS)
Clonazepam ? Klonopin
Paroxetine ? Paxil
Fluoxetine ? Prozac
Sertraline ? Zoloft
1 For references, tables, and boxes, see full report in attached Adobe Acrobat format.
